证券代码：301211 证券简称：亨迪药业 公告编号：2025-046 湖北亨迪药业股份有限公司 第二届董事会第十六次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 会议审议并通过了如下议案： 1、《2025 年第三季度报告》 经审议，董事会认为：公司《2025 年第三季度报告》的编制和审核程序符 合法律、行政法规和中国证券监督管理委员会、深圳证券交易所的规定，报告内 容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈 述或重大遗漏。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）刊载的《2025 年第三季度报告》。 本议案已经公司董事会审计委员会审议通过。 表决结果：赞成 8 票，反对 0 票，弃权 0 票。该项议案获审议通过。 2、《关于补选第二届董事会战略委员会成员的议案》 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第十六次会 议于 2025 年 10 月 16 日以电话及邮件方式送达至全体董事，本次会议于 2025 年 10 月 27 日以现场和通讯方式召 ...

Financial Performance - The company's operating revenue for the third quarter was CNY 841.28 million, a decrease of 8.68% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 23.86 million, down 61.30% year-on-year[5]. - Basic earnings per share decreased by 60.00% to CNY 0.006 compared to the previous year[5]. - Net profit for the current period was CNY 20,933,355.19, down 72% from CNY 74,661,546.28 in the previous period[25]. - Earnings per share (EPS) for the current period was CNY 0.05, compared to CNY 0.18 in the previous period[25]. - The net profit for the first nine months of 2025 was significantly impacted by a 61.46% decrease in net cash flow from operating activities, totaling ¥18,870,338.04 compared to ¥48,958,629.78 in the same period of 2024[14]. Assets and Equity - Total assets as of September 30, 2025, were CNY 2,401,494,054.03, representing a decrease of 3.50% from the end of the previous year[10]. - The company's equity attributable to shareholders was CNY 2,259,307,721.16, down 2.18% from the end of the previous year[10]. - Total assets amounted to CNY 2,401,494,054.03, a slight decrease from CNY 2,488,655,694.01[22]. - Total equity attributable to shareholders was CNY 2,259,307,721.16, compared to CNY 2,309,688,533.16 in the previous period[22]. Cash Flow - The cash flow from operating activities was CNY 18.87 million, a decline of 61.46% compared to the same period last year[5]. - Operating cash inflow for the current period is CNY 313,930,607.85, a decrease from CNY 358,511,330.00 in the previous period, resulting in a net cash flow from operating activities of CNY 18,870,338.04, down from CNY 48,958,629.78[26]. - Cash inflow from investment activities totaled CNY 179,041,323.76, compared to CNY 88,261,830.31 in the previous period, with a net cash flow from investment activities of CNY 46,747,617.31, a significant improvement from a net outflow of CNY 1,085,211,025.10[26]. - Cash outflow from financing activities was CNY 72,815,730.94, down from CNY 138,240,000.00 in the previous period, leading to a net cash flow from financing activities of -CNY 72,815,730.94[27]. - The total cash and cash equivalents at the end of the period is CNY 535,821,483.35, slightly up from CNY 520,745,020.94 in the previous period[27]. Income and Expenses - Non-operating income for the period amounted to CNY 6,258,606.17, a decrease from CNY 20,389,536.01 in the previous year[8]. - The company reported a significant increase in prepayments, which rose by 61.54% to CNY 5,993,392.74 due to increased payments to suppliers[10]. - The company reported a financial expense of CNY -8,147,213.61, a significant improvement from CNY -44,105,422.65 in the previous period[24]. - The income tax expense decreased by 72.43%, amounting to ¥2,183,492.08, primarily due to a reduction in total profit[13]. - Total operating costs increased to CNY 318,613,218.65, up from CNY 263,843,342.98, reflecting a significant rise in operating expenses[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,918[16]. - The largest shareholder, Shanghai Yongda Sheng Business Consulting Co., Ltd., holds 38.25% of the shares, totaling 159,732,000 shares[16]. - The company issued 4.5 new shares for every 10 shares held, increasing the share capital to CNY 417.6 million, a 45.00% increase[12]. Other Information - The company did not report any other items that meet the definition of non-recurring gains and losses[9]. - The company has not yet adopted the new accounting standards effective from 2025[28]. - The third quarter financial report has not been audited[28].

Core Insights - Hendi Pharmaceutical reported that as of October 20, 2025, the number of shareholders is 18,287 [2] Company Summary - Hendi Pharmaceutical is actively engaging with investors through interactive platforms [2] - The company is tracking its shareholder base, indicating a focus on investor relations and transparency [2]

Core Viewpoint - The pharmaceutical sector has experienced significant stock price increases, with Hendi Pharmaceutical reaching a 20% limit-up, and several other companies also showing substantial gains [1] Group 1: Company Performance - Hendi Pharmaceutical's stock surged by 20%, hitting the daily limit [1] - Duori Pharmaceutical's stock rose by over 13% [1] - Other companies such as Guangji Pharmaceutical, Te Yi Pharmaceutical, Hasan Lian, and Chenxin Pharmaceutical also reached their daily limit [1]

Core Viewpoint - The A-share market continues to see an upward trend in flu-related stocks, driven by rising flu activity and concerns over a potentially severe flu season this year [1] Group 1: Stock Performance - Hendi Pharmaceutical has seen a rise of over 18% - Dori Pharmaceutical has increased by over 11% - Guangji Pharmaceutical and Te Yi Pharmaceutical have hit the 10% daily limit up - Chenxin Pharmaceutical has also increased by over 6% - Notably, Guangji Pharmaceutical has achieved two consecutive limit-up days [1] Group 2: Flu Activity and Expert Insights - The China CDC reported that flu activity in northern provinces is currently low, while southern provinces are experiencing an increase - Overall, respiratory disease incidence is showing a slow upward trend nationwide - Experts indicate that the main flu strain this year is likely to be the H3N2 subtype, which was largely absent last year, leading to lower immunity levels in the population - Many experts believe that this year's flu season may arrive earlier and result in a higher number of infections [1]

Group 1 - Pinggao Electric reported a 6.98% increase in revenue to 8.436 billion yuan and a 14.62% increase in net profit to 982 million yuan for the first three quarters of 2025 [1] - Wanchen Group achieved a 77.37% increase in revenue to 36.562 billion yuan and a staggering 917.04% increase in net profit to 855 million yuan for the first three quarters of 2025 [2] - Xintian's revenue decreased by 10.42% to 481 million yuan, with a net profit decline of 35.19% to 91.9 million yuan for the first three quarters of 2025 [3] Group 2 - Chuangye Heima reported a revenue drop of 35.68% to 102 million yuan and a net loss of 24.93 million yuan for the first three quarters of 2025 [4] - Huaxin New Materials saw a 16.11% increase in revenue to 265 million yuan and an 18.56% increase in net profit to 40.81 million yuan for the first three quarters of 2025 [5] - Meihua Medical's revenue increased by 3.28% to 1.194 billion yuan, but net profit fell by 19.25% to 208 million yuan for the first three quarters of 2025 [6] Group 3 - Silica Technology reported a 24.30% increase in revenue to 2.651 billion yuan and a 44.63% increase in net profit to 229 million yuan for the first three quarters of 2025 [7] - Anada experienced a revenue decline of 6.03% to 1.31 billion yuan and a net loss of 46.37 million yuan for the first three quarters of 2025 [8] - StarNet Ruijie achieved a 19.20% increase in revenue to 14.168 billion yuan and a 31.06% increase in net profit to 344 million yuan for the first three quarters of 2025 [9] Group 4 - New Link Electronics reported a revenue decrease of 0.37% to 550 million yuan but a significant net profit increase of 421.43% to 535 million yuan for the first three quarters of 2025 [10] - Tianyin Electromechanical's revenue fell by 22.75% to 581 million yuan, with a net profit decline of 56.10% to 24.27 million yuan for the first three quarters of 2025 [11] - Hengtong Co. reported a revenue decrease of 39.29% to 1.05 billion yuan, but a net profit increase of 78.33% to 176 million yuan for the first three quarters of 2025 [12] Group 5 - Xigao Institute achieved a 15.05% revenue increase to 651 million yuan and a 21.28% net profit increase to 198 million yuan for the first three quarters of 2025 [13] - Good Housewife reported a revenue decrease of 0.91% to 1.059 billion yuan and a net profit decline of 24.79% to 143 million yuan for the first three quarters of 2025 [14] - China Pharmaceutical's subsidiary received approval for Vitamin B6 injection, indicating a positive development in its product pipeline [20] Group 6 - Xi Zhong Technology received approval for the issuance of convertible bonds, indicating potential for future capital raising [22] - Chengda Bio signed a strategic cooperation agreement with the Chinese Academy of Microbiology, focusing on infectious disease prevention [25] - Fuyuan Pharmaceutical received a drug registration certificate for Dydrogesterone tablets, enhancing its product offerings [26] Group 7 - Zhehai Deman received 8.1202 million yuan in land acquisition compensation, indicating a successful resolution of land-related issues [27] - Zhongjin Irradiation announced the resignation of its deputy general manager, indicating potential changes in management [29] - Hendi Pharmaceutical received a drug registration certificate for Febuxostat tablets, expanding its product portfolio [30] Group 8 - David Medical's subsidiary received a medical device registration certificate for a surgical stapler, enhancing its product offerings [32] - Liaoning Energy announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [34] - Fengyuan Co. signed a framework agreement for the supply of lithium iron phosphate, indicating growth in its supply chain [35] Group 9 - Shengda Resources announced the resumption of construction at a mining site, indicating recovery from previous operational disruptions [37] - Shiyuan Co. reported a revenue increase of 5.45% to 18.087 billion yuan, but a net profit decline of 6.81% to 867 million yuan for the first three quarters of 2025 [39] - Feilida reported a revenue decrease of 6.81% to 4.659 billion yuan, but a net profit increase of 49.1% to 33.19 million yuan for the first three quarters of 2025 [40] Group 10 - Changyuan Donggu reported a revenue increase of 29.75% to 1.648 billion yuan and a net profit increase of 76.71% to 274 million yuan for the first three quarters of 2025 [41] - Liyuanheng reported a net profit of 47.49 million yuan for the first three quarters of 2025, indicating stable performance [42] - Fangyuan Co. reported a net loss of 121 million yuan for the first three quarters of 2025, indicating challenges in its operations [43] Group 11 - China Mobile reported a revenue increase of 0.4% to 794.7 billion yuan and a net profit increase of 4% to 115.4 billion yuan for the first three quarters of 2025 [44] - Huangshanghuang reported a revenue decrease of 5.08% to 1.379 billion yuan but a net profit increase of 28.59% to 101 million yuan for the first three quarters of 2025 [46] - Youcai Resources announced plans to invest approximately 150 million yuan in a new materials production base project [47] Group 12 - Huawei Technology announced plans to invest up to 20 million euros in two German subsidiaries [49] - China Shipbuilding projected a net profit increase of 144.42% to 170.85% for the first three quarters of 2025, indicating strong performance [51] - Aeston's subsidiary plans to transfer a 48% stake in a company for 245 million yuan, indicating strategic divestment [52] Group 13 - Jinxinno plans to raise up to 292 million yuan through a private placement, indicating potential for expansion [53] - China Power Construction reported a 5.04% increase in new contract amounts to 904.527 billion yuan for the first three quarters of 2025 [54] - Helitai reported a net profit increase of 101.45% to 17.81 million yuan for the first three quarters of 2025 [55] Group 14 - Xuefeng Technology reported a revenue decrease of 8.28% to 4.183 billion yuan and a net profit decline of 34.6% to 394 million yuan for the first three quarters of 2025 [57] - Juzhi Technology reported a revenue increase of 21.40% to 615 million yuan and a net profit increase of 33.78% to 82.47 million yuan for the first three quarters of 2025 [59] - Jinxi Axle reported a revenue decrease of 0.11% to 872 million yuan but a net profit increase of 268.03% to 22.11 million yuan for the first three quarters of 2025 [60] Group 15 - Longsheng Technology reported a revenue increase of 10.13% to 1.810 billion yuan and a net profit increase of 36.89% to 210 million yuan for the first three quarters of 2025 [62] - Shannon Chip Creation announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [63]

Core Viewpoint - The company, Hendi Pharmaceutical (301211.SZ), has received approval from the National Medical Products Administration for the registration certificate of Febuxostat tablets, which are used for the long-term treatment of hyperuricemia and gout patients [1] Group 1 - The approved drug, Febuxostat tablets, is a xanthine oxidase inhibitor [1] - The primary indication for Febuxostat tablets is the long-term treatment of hyperuricemia and gout, including the management of uric acid levels after acute attacks of gouty arthritis [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Febuxostat tablets, which are intended for the long-term treatment of hyperuricemia and gout patients, marking a significant step in expanding its product line [1] Group 1: Product Registration - The registration of Febuxostat tablets is classified as a Class 4 chemical drug, equivalent to passing the consistency evaluation of generic drug quality and efficacy [1] - This approval allows the company to sell the drug in the domestic market, enhancing its product offerings [1] Group 2: Market Considerations - Future sales of the product may be influenced by national policies, market demand, and competition from similar drugs, indicating potential uncertainties in its market performance [1]

湖北亨迪药业股份有限公司于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的《药品注册证书》，现将相关情况公告如下： 一、药品基本情况 | 药品名称 | 非布司他片 | | --- | --- | | 剂型 | 片剂 | | 规格 | 20mg；40mg | | 注册分类 | 化学药品 4 类 | | 药品有效期 | 18 个月 | | 上市许可持有人 | 湖北亨迪药业股份有限公司 | | 生产企业 | 湖北亨迪药业股份有限公司 | | 受理号 | CYHS2401513；CYHS2401512 | | 证书编号 | 2025S03126、2025S03125 | | 药品批准文号 | 国药准字 H20255686；国药准字 H20255685 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审 | | | 查，本品符合药品注册的有关要求，批准注册，发给药品注 | | | 册证书。质量标准、说明书、标签及生产工艺照所附执行。 | | | 药品生产企业应当符合药品生产质量管理规范要求方可生 | | | 产销售。 | 二、药品的其他相关情况 非布司他片是一种黄嘌呤氧化酶抑制剂，主 ...

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]